Who We Are
Vectura Fertin Pharma brings together Vectura’s expertise in inhalation, Fertin Pharma’s leadership in oral and intra-oral delivery systems, and Philip Morris International’s pre-clinical expertise and worldwide reach and scale. The company aims to build upon products that exist today and make them better for consumers and patients tomorrow.
We will take proven, safe, and effective therapies, unlock their true potential through the application of new and existing consumer and patient-led delivery systems, and commercialize them through proprietary wellness and healthcare brands or in partnership with other pharmaceutical companies.
Our Key Categories
ASPRIHALE® is a dry powder inhalation ASA (acetylsalicylic acid) system, which is designed to reduce the severity of heart attacks. By leveraging a self-administered aerosol and using inhalation as the form of medicine (compared with oral tablets), ASPRIHALE® has demonstrated the potential to accelerate the intended effect of ASA with unprecedented speed and so has the potential to minimize the risk of mortality.
Our Key People
Meet the senior scientists and leaders guiding Vectura Fertin Pharma.